Veitch, Zachary
Zer, Alona
Loong, Herbert
Salah, Samer
Masood, Maryam
Gupta, Abha
Bradbury, Penelope A.
Hogg, David
Wong, Andrew
Kandel, Rita http://orcid.org/0000-0003-4047-3913
Charames, George S.
Abdul Razak, Albiruni R.
Funding for this research was provided by:
Princess Margaret Cancer Foundation
Article History
Received: 26 November 2018
Accepted: 12 April 2019
First Online: 14 May 2019
Competing Interests
: AAR has received research funding from Roche, Genentech, Eli Lilly, Merck, Boehringer Ingleheim, Novartis, Abbvie, Deciphera, Karyopharm, Astra Zeneca, Medimmune, Blueprint, Bristol Myers Squibb, GSK, Entremed/Casi Pharmaceuticals, BetaCat. He also has also served the advisory board for Eli Lilly, Merck, Boehringer Ingleheim. HL has received researching funding from Merck and Mundipharma. He has also served or is currently serving on the advisory boards of Boehringer Ingleheim, Eli Lilly, Novartis, LOXO Pharmaceuticals, Roche/Genentech. He has received speakers’ fees from AbbVie, Bayer, Eisai Pharmaceuticals, Eli-Lilly and Novartis. The following authors have declared no conflicts of interest: ZV, AZ, SS, MM, AG, PB, DH, AW, RK, GC.